drugset / Trial / NCT07033533

Allopurinol and Pathogenesis of Cirrhosis

NCT07033533

Phase 1/2 Completed 100 enrolled Tanta University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Hepatic decompensation is a common healthcare issue . This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Timeline

Start
2023-06-01
Primary completion
2024-03-01
Completion
2024-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule

Indications